Yahoo Finance2h
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the ...
GlobalData on MSN22h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
FierceBiotech1d
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
Q32 Bio downgraded to Neutral at Guggenheim after failure in atopic dermatitis
As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...
Too Old to Operate1d
Dupilumab Efficacious for Atopic Dermatitis in Young Children
Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
dermatologyadvisor1d
Increased Bipolar Disorder Risk Is Linked to Atopic Dermatitis in US Population
Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.
Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis
Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U ...